I et randomiseret, sammenlignende fase III- studie, udført af Gynaecological Oncology Group (GOG 0179), blev topotecan + cisplatin (n = 147) sammenlignet med cisplatin alene (n = 146) for behandling af histologisk bekræftet, persisterende, recidiverende eller stadium IVB- cervixcancer, hvor kurativ intenderet behandling med kirurgi og/ eller stråleterapi ikke var vurderet hensigtsmæssig.
In a randomised, comparative phase III trial conducted by the Gynaecological Oncology Group (GOG 0179), topotecan plus cisplatin (n=147) was compared with cisplatin alone (n=146) for the treatment of histologically confirmed persistent, recurrent or Stage IVB carcinoma of the cervix where curative treatment with surgery and/ or radiation was not considered appropriate.